RETROTOPE UPDATE!
I will be meeting with the RETROTOPE team tomorrow March 5th in California and will provide an update shortly after.
In the interim here is an update from Sarah for all who have been inquiring about the upcoming PSP Trials with RT001.
Please share amongst your networks to help spread the word and Hope!
Dear Laura:
It was a pleasure speaking with you last week. As discussed, we have been inundated with requests for more information. Due to the high volume of calls and emails it will take some time to respond to everyone, but you can assure your members that everyone will receive a response typically within 14 business days. In the interim, I have prepared some information that you can share with your group.
Retrotope is in the process of developing drugs to treat a variety of neurological diseases, and PSP is a disease that we intend to target. We have treated a few patients in the U.S. with our investigational drug candidate RT001, and we have seen encouraging results. These results have prompted us to plan a clinical trial for PSP and this is likely to begin sometime in summer 2020.
The trial will take place at several centers within the United States. If a patient with PSP meets all trial criteria and is willing and able to travel every few months to a U.S. medical center that is participating in the trial, she or he may be able to enroll in our study. Due to regulatory restrictions, at present we are not able to treat at sites outside of the U.S.
As the trial start nears, a formal listing regarding the trial and participating clinical trial sites will be posted on https://clinicaltrials.gov/.
PSP Awareness will be notified when this listing goes live. Patients may additionally reach out to me and request that I place them on our list of patients to contact for the trial. The best way to reach me is via email, sarah@retrotope.com.
Retrotope believes that we can best serve the PSP community through formal clinical testing of RT001 in the above noted clinical trial. Rest assured PSP for multiple reasons is a very high priority for Retrotope. At this time Retrotope does not plan to authorize additional use of RT001 for PSP, such as new Expanded Access PSP treatment, outside of testing in the planned clinical trial.
We thank you and the PSP community for such a warm welcome and we look forward to continued partnership over the course of the trial.
Sarah Endemann, MSc, CCRC
Clinical Coordinator
Retrotope, Inc.
4300 El Camino Real, Ste. 201
Los Altos, CA 94022
sarah@retrotope.com
www.retrotope.com
#PSPAwareness #CurePSP #PSPAssociation #pspclinicaltrial #RT001 #ProgressiveSupranuclearPalsy #Retrotope
